ASX:PAA - PharmAust New cancer treatment available for dogs with Lymphoma

Wednesday, November 6, 2019 9:40 PM +00:00

ASX:PAA - PharmAust New cancer treatment avai...0:0012:43
LIVEQuality1  AudioSubtitleDownloadSpeed1  
PHARMAUST LIMITED
Roger Aston

PharmAust Limited (ASX: PAA) is pleased to announce that its new clinical trial in partnership with U-Vet Werribee Animal Hospital is currently recruiting. The trial will evaluate the drug monepantel, which has shown promising anti-cancer results in vitro, in mice and in previous preliminary investigations in dogs with lymphoma as well as in a Phase I study in humans with cancer.


Leave a Comment

Your email address will not be published

WEBCAST Calendar

  • 16 Mar

    02:00

    Working Together During Coronavirus Outbreak

    CISCO SYSTEMS
  • 16 Mar

    02:00

    FYI Resources DFS highlights low capital and operating costs for kaolin and HPA project

    FYI RESOURCES LIMITED
  • 16 Mar

    02:00

    Eli Lilly CEO talks partnering with AbCellera Biologics to co-develop a coronavirus cure 14.03.2020

    ELI LILLY AND COMPANY
  • 16 Mar

    02:00

    amaysim Australia Ltd (AYS) CEO & Managing Director, Peter O’Connell 11.03.2020

    AMAYSIM AUSTRALIA LIMITED
  • 16 Mar

    02:00

    2021 Ford Mustang Mach-E: Winter Testing All-Wheel Drive | Ford 13.03.2020

    FORD MOTOR COMPANY